ArticleBlood advances2023

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.

Michael Scordo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.